Robert Lane

Robert Lane is a clinical researcher with a focus on pharmacological interventions for depressive disorders, particularly rapid-acting glutamatergic agents. He has been involved as an investigator on multiple randomised, double-blind, multicentre clinical trials assessing the efficacy and safety of esketamine nasal spray in adults and adolescents with treatment-resistant depression and in patients with active suicidal ideation and intent. His work spans large Phase 3 programmes, including pooled analyses of ASPIRE I and ASPIRE II, studies of flexibly dosed esketamine in combination with oral antidepressants, and trials of esketamine monotherapy.

Lane's contributions emphasise clinical trial design and execution, patient-reported outcomes, and safety characterisation in high-risk populations. He has helped generate data on rapid symptom reduction, effects on suicidality, and tolerability in diverse cohorts, including adolescents at imminent suicide risk, thereby informing clinical use and regulatory discussions surrounding esketamine as a treatment option for severe and refractory depressive illnesses.